All patients
invasive ventilation non invasive oxygen
remdesivir in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50]
GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86]
Mahajan, 2021 1.23 [0.34; 4.42]
NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03]
0.75 [0.54 ; 1.03 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Mahajan, 2021, NIH NIAID ACTT-1, 2020 4 0% 1,928 moderate not evaluable deathsdetailed results CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45]
GS-US-540-5773 (Goldman), 2020 (REV) 1.37 [0.69; 2.72]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
Mahajan, 2021 1.23 [0.34; 4.42]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
0.88 [0.68 ; 1.14 ] CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Mahajan, 2021, NIH NIAID ACTT-1, 2020, SOLIDARITY (remdesivir), 2020 7 27% 8,024 moderate not evaluable deaths (time to event analysis only)detailed results GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
0.75 [0.50 ; 1.12 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020, SOLIDARITY (remdesivir), 2020 4 52% 7,309 moderate not evaluable clinical deteriorationdetailed results CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64]
0.95 [0.55 ; 1.64 ] CAP-China (Wang et al.), 2020 1 0% 237 NA not evaluable clinical improvementdetailed results CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
GS-US-540-5773 (Goldman), 2020 (REV) 1.27 [0.98; 1.63]
GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74]
GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
1.29 [1.16 ; 1.44 ] CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020 5 0% 2,492 moderate not evaluable clinical improvement (14-day)detailed results CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28]
GS-US-540-5773 (Goldman), 2020 (REV) 0.65 [0.44; 0.98]
GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47]
GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44]
1.17 [0.74 ; 1.85 ] CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 4 73% 1,417 moderate not evaluable clinical improvement (28-day)detailed results CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39]
GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42]
GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17]
NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76]
1.45 [1.18 ; 1.79 ] CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020 4 0% 2,082 moderate not evaluable clinical improvement (7-day)detailed results CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51]
GS-US-540-5773 (Goldman), 2020 (REV) 0.69 [0.45; 1.05]
GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53]
GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09]
1.00 [0.70 ; 1.43 ] CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 4 48% 1,417 moderate not evaluable clinical improvement (time to event analysis only)detailed results CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
GS-US-540-5773 (Goldman), 2020 (REV) 1.27 [0.98; 1.63]
GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44]
GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
1.23 [1.12 ; 1.35 ] CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020 5 0% 2,492 moderate not evaluable death or ventilationdetailed results SOLIDARITY (remdesivir), 2020 0.97 [0.85; 1.10]
0.97 [0.85 ; 1.10 ] SOLIDARITY (remdesivir), 2020 1 0% 5,451 NA not evaluable mechanical ventilationdetailed results GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30]
GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45]
Mahajan, 2021 2.27 [0.39; 13.27]
SOLIDARITY (remdesivir), 2020 1.04 [0.87; 1.23]
0.87 [0.39 ; 1.96 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Mahajan, 2021, SOLIDARITY (remdesivir), 2020 4 29% 5,818 moderate not evaluable recoverydetailed results GS-US-540-5773 (Goldman), 2020 (REV) 1.23 [0.97; 1.57]
GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37]
GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45]
1.17 [1.03 ; 1.33 ] GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,193 moderate not evaluable AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 2.43 [0.79; 7.45]
2.43 [0.79 ; 7.45 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable serious adverse eventsdetailed results CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23]
GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23]
GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14]
NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96]
0.67 [0.53 ; 0.85 ] CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020 4 0% 2,080 moderate not evaluable adverse eventsdetailed results GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42]
GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80]
1.40 [1.05 ; 1.87 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 4% 784 moderate not evaluable deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81]
0.62 [0.23 ; 1.64 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 0.36 [0.13; 1.01]
NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18]
0.58 [0.34 ; 0.97 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 6% 1,296 moderate not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 1.09 [0.42; 2.79]
NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34]
0.97 [0.48 ; 1.93 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 low not evaluable pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80]
0.82 [0.20 ; 3.29 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 1.01 [0.03; 30.33]
NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61]
1.02 [0.64 ; 1.61 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable serious adverse events (SAE), anydetailed results GS-US-540-5773 (Goldman), 2020 (REV) 1.98 [1.27; 3.11]
1.98 [1.27 ; 3.11 ] GS-US-540-5773 (Goldman), 2020 (REV) 1 0% 397 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:06 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 510
- roots T: 290